A new publication by Prof. Francesco Bertoni LAB

Antibody-drug conjugates (ADCs) are an effective therapeutic modality to deliver potent cytotoxic molecules to tumor cells bearing a specific antigen. Following their previous work on the anti-CD19 ADCs huB4-DGN462 and coltuximab ravtansine (SAR3419) (PMID 30733273), the research team led by Prof. Francesco Bertoni has now characterized the novel ADC MEN1309/OBT076 targeting CD205 for its anti- lymphoma activity.

The work done by Dr Eugenio Gaudio, Dr Chiara Tarantelli and Colleagues, now published in the journal Haematologica, have provided the rationale to explore the compound in patients with relapsed or refractory CD205-positive lymphoma in the on-going phase I study (NCT03403725).

Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models

by Eugenio Gaudio*, Chiara Tarantelli*, Filippo Spriano, Francesca Guidetti, Giulio Sartori, Roberta Bordone, Alberto J. Arribas, Luciano Cascione, Mario Bigioni, Giuseppe Merlino, Alessio Fiascarelli, Alessandro Bressan, Afua Adjeiwaa Mensah, Gaetanina Golino, Renzo Lucchini, Elena Bernasconi, Davide Rossi, Emanuele Zucca, Georg Stussi, Anastasios Stathis, Robert S. Boyd, Rachel L. Dusek, Arnima Bisht, Nickolas Attanasio, Christian Rohlff, Andrea Pellacani, Monica Binaschi, and Francesco Bertoni

*, co-first authors.

 

Haematologica. 2020 Jan 9. pii: haematol.2019.227215. doi: 10.3324/haematol.2019.227215. [Epub ahead of print]

http://www.haematologica.org/content/early/2020/01/03/haematol.2019.227215.long

https://www.ncbi.nlm.nih.gov/pubmed/31919082